Neural correlates of interactions between cannabidiol and Δ(9) -tetrahydrocannabinol in mice: implications for medical cannabis

British Journal of Pharmacology
S M Todd, Jonathon C Arnold

Abstract

It has been proposed that medicinal strains of cannabis and therapeutic preparations would be safer with a more balanced concentration ratio of Δ(9) -tetrahydrocannabinol (THC) to cannabidiol (CBD), as CBD reduces the adverse psychotropic effects of THC. However, our understanding of CBD and THC interactions is limited and the brain circuitry mediating interactions between CBD and THC are unknown. The aim of this study was to investigate whether CBD modulated the functional effects and c-Fos expression induced by THC, using a 1:1 dose ratio that approximates therapeutic strains of cannabis and nabiximols. Male C57BL/6 mice were treated with vehicle, CBD, THC or a combination of CBD and THC (10 mg·kg(-1) i.p. for both cannabinoids) to examine effects on locomotor activity, anxiety-related behaviour, body temperature and brain c-Fos expression (a marker of neuronal activation). CBD potentiated THC-induced locomotor suppression but reduced the hypothermic and anxiogenic effects of THC. CBD alone had no effect on these measures. THC increased brain activation as measured by c-Fos expression in 11 of the 35 brain regions studied. CBD co-administration suppressed THC-induced c-Fos expression in six of these brain regions. This effect...Continue Reading

References

Jul 30, 1969·Annals of the New York Academy of Sciences·V H Denenberg
Jan 30, 2002·British Journal of Pharmacology·Emmanuel ValjentRafael Maldonado
May 26, 2004·Life Sciences·Viviane M C GuimarãesFrancisco S Guimarães
May 3, 2005·Brain Research·Urban KarlssonJohannes J Krupp
Oct 4, 2005·Life Sciences·Mahmoud A Elsohly, Desmond Slade
Jan 28, 2006·The Journal of Pharmacology and Experimental Therapeutics·Hao-Jie ZhuC Lindsay Devane
Mar 31, 2006·Psychopharmacology·S A VarvelB R Martin
Oct 2, 2007·British Journal of Pharmacology·M L HollandJ C Arnold
Feb 20, 2008·Planta medica·Mohamed M RadwanMahmoud A Elsohly
Apr 2, 2008·The British Journal of Psychiatry : the Journal of Mental Science·Celia J A Morgan, H Valerie Curran
Apr 28, 2009·Pharmacology, Biochemistry, and Behavior·Daniel Thomas MaloneDavid Alan Taylor
Sep 30, 2009·The International Journal of Neuropsychopharmacology·Leonora E LongTim Karl
Jul 8, 2010·The Journal of Gene Medicine·Carol KilkennyUNKNOWN NC3Rs Reporting Guidelines Working Group
Jul 17, 2010·The Journal of Physiology·UNKNOWN NC3Rs Reporting Guidelines Working Group
Jul 24, 2010·British Journal of Pharmacology·J C McGrathC L Wainwright
Jul 24, 2010·British Journal of Pharmacology·Carol KilkennyUNKNOWN NC3Rs Reporting Guidelines Working Group
Aug 13, 2010·The International Journal of Neuropsychopharmacology·Aurélie A BoucherJonathon C Arnold
Nov 16, 2010·Nature Neuroscience·Andrés E ChávezPablo E Castillo
Feb 11, 2011·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Mateus M BergamaschiJosé Alexandre S Crippa
Feb 11, 2011·Current Topics in Behavioral Neurosciences·Fabrício A Moreira, Carsten T Wotjak
Apr 1, 2011·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Daniel J CavanaughAllan I Basbaum
Jul 14, 2011·British Journal of Pharmacology·Ethan B Russo
Sep 9, 2011·American Journal of Physiology. Regulatory, Integrative and Comparative Physiology·Kazuhiro Nakamura
Sep 23, 2011·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Plínio C CasarottoFabrício A Moreira
Jan 28, 2012·Recent Patents on CNS Drug Discovery·Onintza SagredoJavier Fernandez-Ruiz

❮ Previous
Next ❯

Citations

Mar 3, 2017·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·T BakasM Chebib
Jan 4, 2017·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Stephanie M ToddJonathon C Arnold
Sep 7, 2017·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Douglas L BoggsMohini Ranganathan
Feb 6, 2019·Pain and Therapy·Ivan UritsOmar Viswanath
Jan 31, 2019·Drug Testing and Analysis·Michael KraemerCornelius Hess
Mar 9, 2017·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Natalia I BrzozowskaJonathon C Arnold
Jan 19, 2018·Journal of Epilepsy Research·Emilio Perucca
Dec 10, 2016·Frontiers in Pharmacology·Regimantas JurkusCarl W Stevenson
Jul 4, 2018·Medicines·Sherelle L Casey, Christopher W Vaughan
Sep 29, 2019·Evidence-based Complementary and Alternative Medicine : ECAM·Gioacchino CalapaiFabio Firenzuoli
Apr 29, 2019·Current Psychiatry Reports·Eleni P Papagianni, Carl W Stevenson
Aug 3, 2019·Drugs·Valentina Franco, Emilio Perucca
Dec 13, 2019·Progress in Neuro-psychopharmacology & Biological Psychiatry·Madelyne A BisbyKathryn D Baker
Jan 31, 2021·Journal of General Internal Medicine·Premalatha BalachandranKevin P Hill
Oct 30, 2020·Frontiers in Pharmacology·Umberto RaucciPasquale Parisi
Jun 12, 2021·Neuropharmacology·Gavin N PetrieMatthew N Hill
Jul 11, 2021·Journal of Cannabis Research·Carole M LindsayTainia T Taylor

❮ Previous
Next ❯

Related Concepts

Related Feeds

Amygdala and Midbrain Dopamine

The midbrain dopamine system is widely studied for its involvement in emotional and motivational behavior. Some of these neurons receive information from the amygdala and project throughout the cortex. When the circuit and transmission of dopamine is disrupted symptoms may present. Here is the latest research on the amygdala and midbrain dopamine.

Amygdala: Sensory Processes

Amygdalae, nuclei clusters located in the temporal lobe of the brain, play a role in memory, emotional responses, and decision-making. Here is the latest research on sensory processes in the amygdala.